GC001 injection for returning or growing high-grade brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with a high-grade glioma (WHO grade 3 or 4) that has returned or is growing despite treatment.
- You have at least one measurable tumor on an MRI that is larger than 10 mm.
- You are willing to have a small device (Ommaya reservoir) placed during a procedure to receive the drug.
- You are able to care for yourself most of the day (Karnofsky score 60 or higher) and expected to live at least 3 months.
- Your blood counts, liver, and kidney functions are within certain safe limits.
- You have not had certain other cancers, infections, severe heart conditions, or recent major treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy given directly into the brain tumor. It's for people with high-grade glioma, either newly diagnosed or after one recurrence, to see if it can help control the tumor.
This trial tests a new treatment that combines a specially designed virus to attack tumor cells with an immunotherapy drug to help the immune system fight the cancer. It is for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment.
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
This trial tests a new medicine called C5252 for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment. The medicine is given directly into the brain through a small device placed under the scalp (Ommaya reservoir) after surgery to remove as much of the tumor as possible.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Hear when a new High-grade Gliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.